Inhibition Effect of Pancreatic Exocrine Insufficiency on Immune Checkpoint Inhibitor Treatment in Pancreatic Cancer: A Retrospective Study

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Renouf DJ, Loree JM, Knox JJ, et al. The CCTG PA.7 Phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022;13(1):5020. doi:10.1038/s41467-022-32591-8
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. doi:10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Schonfeld SJ, Tucker MA, Engels EA, et al. Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults. JAMA Network Open. 2022;5(3):e223461. doi:10.1001/jamanetworkopen.2022.3461
   PubMed Web of Science ®Google Scholar
• Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17–30. doi:10.1016/j.ctrv.2019.06.005
   PubMed Web of Science ®Google Scholar
• Kabacaoglu D, Ciecielski KJ, Ruess DA, et al. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol. 2018;9:1878. doi:10.3389/fimmu.2018.01878
   PubMed Web of Science ®Google Scholar
• Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014;25(9):1750–1755. doi:10.1093/annonc/mdu205
   PubMed Web of Science ®Google Scholar
• Padrón LJ, Maurer DM, O’Hara MH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized Phase 2 PRINCE trial. Nat Med. 2022;28(6):1167–1177. doi:10.1038/s41591-022-01829-9
   PubMed Web of Science ®Google Scholar
• Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a Phase Ib study. Oncologist. 2020;25(5):e808–e815. doi:10.1634/theoncologist.2019-0473
   PubMed Web of Science ®Google Scholar
• Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treat Rev. 2020;86:102016. doi:10.1016/j.ctrv.2020.102016
   PubMed Web of Science ®Google Scholar
• Prasanna T, McNeil CM, Nielsen T, Parkin D. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy. 2018;10(3):171–175. doi:10.2217/imt-2017-0126
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang H, Zhou L, et al. Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management. Front Oncol. 2021;11:627612. doi:10.3389/fonc.2021.627612
   PubMed Web of Science ®Google Scholar
• Domínguez-Muñoz JE, Nieto-Garcia L, López-Díaz J, et al. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer. 2018;18(1):534. doi:10.1186/s12885-018-4439-x
   PubMedGoogle Scholar
• Pezzilli R, Caccialanza R, Capurso G, Brunetti O, Milella M, Falconi M. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers. 2020;12(2):275. doi:10.3390/cancers12020275
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol. 2022;79:18–43. doi:10.1016/j.semcancer.2020.07.001
   PubMed Web of Science ®Google Scholar
• Li X, Gulati M, Larson AC, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86(Pt 2):14–27. doi:10.1016/j.semcancer.2022.08.009
   PubMedGoogle Scholar
• Dias Costa A, Väyrynen SA, Chawla A, et al. Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer. Clin Cancer Res. 2022;28(23):5167–5179. doi:10.1158/1078-0432.CCR-22-1125
   PubMed Web of Science ®Google Scholar
• Michelakos T, Cai L, Villani V, et al. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. J Natl Cancer Inst. 2021;113(2):182–191. doi:10.1093/jnci/djaa073
   PubMedGoogle Scholar
• Brooks J, Fleischmann-Mundt B, Woller N, et al. Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer. Cancer Res. 2018;78(2):475–488. doi:10.1158/0008-5472.CAN-17-2415
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018;36(1):96–102. doi:10.1007/s10637-017-0525-1
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Hochster HS, Kim EJ, et al. Open-label, Phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin Cancer Res. 2020;26(18):4814–4822. doi:10.1158/1078-0432.CCR-20-0099
   PubMed Web of Science ®Google Scholar
• Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroenterol J. 2020;8(9):1115–1125. doi:10.1177/2050640620938987
   PubMed Web of Science ®Google Scholar
• Roeyen G, Berrevoet F, Borbath I, et al. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open. 2022;7(1):100386. doi:10.1016/j.esmoop.2022.100386
   PubMed Web of Science ®Google Scholar
• Vujasinovic M, Valente R, Del Chiaro M, Permert J, Löhr JM. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017;9(3):183. doi:10.3390/nu9030183
   PubMed Web of Science ®Google Scholar
• Ru N, Zou WB, Wu H, et al. Chinese guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency (2018 edition). J Dig Dis. 2019;20(11):567–571. doi:10.1111/1751-2980.12753
   PubMed Web of Science ®Google Scholar
• Phillips ME, Hopper AD, Leeds JS, et al. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021;8(1):e000643. doi:10.1136/bmjgast-2021-000643
   PubMed Web of Science ®Google Scholar
• Lan X, Robin G, Kasnik J, Wong G, Abdel-Rahman O. Challenges in diagnosis and treatment of pancreatic exocrine insufficiency among patients with pancreatic ductal adenocarcinoma. Cancers. 2023;15(4):1331. doi:10.3390/cancers15041331
   PubMed Web of Science ®Google Scholar